Clinical trial · Interventional
Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors (NEUROSEX)
Early Detection and Paramedical Care of Sexual Difficulties in Nervous System Diseases: Example of Multiple Sclerosis and Brain Tumors
NCT03154801CI-TRIAL-00056625NEUROSEXunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aim to ensure that the implementation of a paramedical screening program and counseling in sexual health of patients with neurological pathologies (low-grade gliomas and Multiple Sclerosis) improves their sexual health.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Low Grade Glioma of Brain | — | UNRESOLVED | — |
| Multiple Sclerosis | — | UNRESOLVED | — |
| Sexual Dysfunctions | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paramedical care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Paramedical care
- description
- paramedical early detection of sexual dysfunction and sexual health counseling
- interventionNames
- Other: Paramedical care
Primary outcomes (1)
- measure
- Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)
- timeFrame
- Inclusion and 3 months
- description
- Change of MSISQ15 sexual dysfunctional items at 3-months from baseline
Secondary outcomes (13)
- measure
- Change of MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire)
- timeFrame
- Inclusion and 6-months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Any major patient, followed in the GHPSCF (Groupe Hospitalier Pitié-Salpêtrière Charles Foix) neurology department 2 for a diagnosis of low grade glioma or anaplastic glioma with loss 1p / 19q sub-reserve histo-molecular confirmation after national reading (POLA) and presenting: * An MSISQ15 (Multiple Sclerosis Intimacy and Sexuality Questionnaire) questionnaire with at least one of the items rated "4" or "5" and * A HAD (Hospital Anxiety and Depression) questionnaire (depression component) with a score ≤ 11 2. Any major patient with MS(Multiple Sclerosis), followed in the GHPSCF Department of Neurology: * With an EDSS (Expanded Disability Status Scale) greater than or equal to 1 and * An MSISQ15 questionnaire with at least one of the items rated "4" or "5". * A HAD questionnaire (depression component) with a score ≤ 11 3. Signature of informed consent 4. Patient affiliated to a social security system Exclusion Criteria: 1. Minor patients 2. Pregnant women 3. Patients who do not understand and / or speak French and / or are unable to sign consent 4. Patients with neurological impairment 5. Patients with chronic sexual disorders who have already received treatment. 6. Patients with a HAD score (depression component) greater than 11 7. Patients with MS who had a corticosteroid-treated outbreak in the last two months. 8. Patients with low-grade glioma with clinical and / or radiological scalability during the last three months 9. Any patient whose alteration of the general state would not allow to follow the program. 10. Patients under legal protection For patient's partners: Inclusion criteria: 1. Any patient partner, whose patient has wished to participate and who has accepted. 2. Signing of informed consent Non-Inclusion Criteria: 1. Minor partners 2. Pregnant women 3. Any person who does not understand and / or speak French and / or is unable to sign the consent 4. Partners under legal protection
References
Publications (0)
Data not yet available
No reference posted for this study.